170 related articles for article (PubMed ID: 31124055)
1. Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.
Ebata T; Shimizu T; Fujiwara Y; Tamura K; Kondo S; Iwasa S; Yonemori K; Shimomura A; Kitano S; Koyama T; Sato N; Nakai K; Inatani M; Yamamoto N
Invest New Drugs; 2020 Apr; 38(2):468-477. PubMed ID: 31124055
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Jung KH; LoRusso P; Burris H; Gordon M; Bang YJ; Hellmann MD; Cervantes A; Ochoa de Olza M; Marabelle A; Hodi FS; Ahn MJ; Emens LA; Barlesi F; Hamid O; Calvo E; McDermott D; Soliman H; Rhee I; Lin R; Pourmohamad T; Suchomel J; Tsuhako A; Morrissey K; Mahrus S; Morley R; Pirzkall A; Davis SL
Clin Cancer Res; 2019 Jun; 25(11):3220-3228. PubMed ID: 30770348
[TBL] [Abstract][Full Text] [Related]
3. Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
Nayak-Kapoor A; Hao Z; Sadek R; Dobbins R; Marshall L; Vahanian NN; Jay Ramsey W; Kennedy E; Mautino MR; Link CJ; Lin RS; Royer-Joo S; Liang X; Salphati L; Morrissey KM; Mahrus S; McCall B; Pirzkall A; Munn DH; Janik JE; Khleif SN
J Immunother Cancer; 2018 Jun; 6(1):61. PubMed ID: 29921320
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
Kotecki N; Vuagnat P; O'Neil BH; Jalal S; Rottey S; Prenen H; Benhadji KA; Xia M; Szpurka AM; Saha A; Wallin J; Suriyapperuma S; Galvao VR; Geeganage S; Doman TN; Gandhi L; Xu X; Bendell J
J Immunother; 2021 Sep; 44(7):264-275. PubMed ID: 33928928
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor.
Ma S; Suchomel J; Yanez E; Yost E; Liang X; Zhu R; Le H; Siebers N; Joas L; Morley R; Royer-Joo S; Pirzkall A; Salphati L; Ware JA; Morrissey KM
Br J Clin Pharmacol; 2019 Aug; 85(8):1751-1760. PubMed ID: 30973970
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer.
Hellmann MD; Gettinger S; Chow LQM; Gordon M; Awad MM; Cha E; Gong X; Zhou G; Walker C; Leopold L; Heist RS
Int J Cancer; 2020 Oct; 147(7):1963-1969. PubMed ID: 32141617
[TBL] [Abstract][Full Text] [Related]
7. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.
Reardon DA; Desjardins A; Rixe O; Cloughesy T; Alekar S; Williams JH; Li R; Taylor CT; Lassman AB
Invest New Drugs; 2020 Dec; 38(6):1784-1795. PubMed ID: 32436060
[TBL] [Abstract][Full Text] [Related]
9. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
Sanborn RE; Hamid O; de Vries EG; Ott PA; Garcia-Corbacho J; Boni V; Bendell J; Autio KA; Cho DC; Plummer R; Stroh M; Lu L; Thistlethwaite F
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301808
[TBL] [Abstract][Full Text] [Related]
10. Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody.
Harding JJ; Moreno V; Bang YJ; Hong MH; Patnaik A; Trigo J; Szpurka AM; Yamamoto N; Doi T; Fu S; Calderon B; Velez de Mendizabal N; Calvo E; Yu D; Gandhi L; Liu ZT; Galvao VR; Leow CC; de Miguel MJ
Clin Cancer Res; 2021 Apr; 27(8):2168-2178. PubMed ID: 33514524
[TBL] [Abstract][Full Text] [Related]
11. PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.
Kuboki Y; Koyama T; Matsubara N; Naito Y; Kondo S; Harano K; Yonemori K; Yoh K; Gu Y; Mita T; Chen X; Ueda E; Yamamoto N; Doi T; Shimizu T
Cancer Med; 2024 Apr; 13(8):e6980. PubMed ID: 38651187
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors.
Mizugaki H; Yamamoto N; Murakami H; Kenmotsu H; Fujiwara Y; Ishida Y; Kawakami T; Takahashi T
Invest New Drugs; 2016 Oct; 34(5):596-603. PubMed ID: 27363843
[TBL] [Abstract][Full Text] [Related]
13. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
Hellmann MD; Kim TW; Lee CB; Goh BC; Miller WH; Oh DY; Jamal R; Chee CE; Chow LQM; Gainor JF; Desai J; Solomon BJ; Das Thakur M; Pitcher B; Foster P; Hernandez G; Wongchenko MJ; Cha E; Bang YJ; Siu LL; Bendell J
Ann Oncol; 2019 Jul; 30(7):1134-1142. PubMed ID: 30918950
[TBL] [Abstract][Full Text] [Related]
14. Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.
Bishnoi S; Kotasek D; Aghmesheh M; Yau T; Cosman R; Prawira A; Moore M; Chan SL; Mant A; Eek R; Zielinski R; Su R; Pan Z; Ma Y; Li F; Li P; Tse AN
Cancer; 2024 Jun; 130(11):1991-2002. PubMed ID: 38404184
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
16. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ
Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis.
Li DN; Lu WQ; Yang BW; Zhang LY; Jin B; Wang S; Che XF; Li C; Liu YP; Qu XJ
Front Immunol; 2021; 12():666909. PubMed ID: 34149702
[TBL] [Abstract][Full Text] [Related]
18. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni A; Azevedo S; Rubio-Viqueira B; Rodríguez-Abreu D; Alatorre-Alexander J; Smit HJM; Yu J; Syrigos K; Trunzer K; Patel H; Tolson J; Cardona A; Perez-Moreno PD; Newsom-Davis T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
